Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 7, 2006; 12(33): 5272-5280
Published online Sep 7, 2006. doi: 10.3748/wjg.v12.i33.5272
Published online Sep 7, 2006. doi: 10.3748/wjg.v12.i33.5272
Hepatitis C | Hepatitis B | Fatty liver | Hemochromatosis | |
Disease common and causing morbidity/mortality | Yes | Yes | Common, but increased mortality only if advanced NASH | Common, but only 1% of screened population with complications[13] |
Target population identifiable | High risk groups | High risk groups | Obese, diabetics | Northern European ancestry |
Screening test | HCV Antibody test | HBsAg test | Ultrasound | Transferrin saturation or genetic testing (unsettled) |
Performance of test | Good | Good | Low PPV and NPV for fibrosis | Under investigation |
Effective therapy | 50% cure[14] | 4%-24% HBsAg loss, 70% no progression[15,16] | Only lifestyle modification | Yes, but may be unnecessary |
- Citation: Poggio PD, Mazzoleni M. Screening in liver disease. World J Gastroenterol 2006; 12(33): 5272-5280
- URL: https://www.wjgnet.com/1007-9327/full/v12/i33/5272.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i33.5272